Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where ...

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

The company has agreed a nationally available price reduction for somapacitan with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence. The ...

Somapacitan can be used, within its marketing authorisation, as an option to treat growth failure caused by growth hormone deficiency in people 3 to 17 years. Somapacitan can be used if the company ...

The highly specialised technologies evaluation committee is a standing advisory committee of NICE. This topic was considered as a cost comparison evaluation by the lead team of the highly specialised ...

Somapacitan (Sogroya, Novo Nordisk) is indicated 'for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Somapacitan (Sogroya) is available on the NHS. It is a possible treatment for growth failure caused by growth hormone deficiency in people 3 to 17 years. Is this treatment right for me or my child?

Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) TA1068 29 May 2025 29 May 2025 Nivolumab plus ipilimumab for ...

Date Update 09 June 2025 The resolution start date for this topic has been delayed. The revised timeline for the evaluation will be available on the topic webpage in due course.

This guidance has been updated and replaced by NICE guideline NG217. Back to top ...